secwatch.observer — SEC 8-K summary
======================================

Issuer:     Personalis, Inc. (PSNL)
CIK:        0001527753
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0000950170-24-122230
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Personalis Q3 revenue $25.7M (+41% YoY); raises FY 2024 guidance to $83-84M
---------------------------------------------------------------------------

- Revenue $25.7M, up 41% YoY; biopharma revenue $15.7M (+96% YoY).
- Net loss $39.1M includes $26.0M non-cash warrant expense; cash $143.7M.
- Raised FY2024 revenue guidance to $83-84M from $79-81M; Q4 revenue expected $15-16M.
- Delivered 945 molecular tests in Q3, a 68% sequential increase.
- Raised ~$62.2M net from Tempus warrant exercise and ATM stock sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527753/000095017024122230/0000950170-24-122230-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527753/000095017024122230/psnl-20241106.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-122230

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer